Dae Gon Ha
Stock Analyst at Stifel
(3.02)
# 1,179
Out of 4,479 analysts
38
Total ratings
38.71%
Success rate
2.83%
Average return
Main Sectors:
Top Industries:
21 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $33.68 | +95.96% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $40.96 | +210.06% | 2 | May 31, 2024 | |
| ABEO Abeona Therapeutics | Initiates: Buy | $21 | $4.12 | +409.71% | 1 | May 30, 2024 | |
| KRYS Krystal Biotech | Reiterates: Buy | $178 → $204 | $177.61 | +14.86% | 3 | Apr 16, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $5.00 | +700.00% | 3 | Apr 3, 2024 | |
| SLNO Soleno Therapeutics | Initiates: Buy | $63 | $39.73 | +58.57% | 1 | Jan 23, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $9 → $17 | $4.54 | +274.45% | 2 | Sep 29, 2023 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $19.78 | +142.67% | 4 | Sep 13, 2023 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $11 | $6.10 | +80.33% | 3 | Aug 22, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $5.28 | +240.91% | 1 | Apr 18, 2023 | |
| EQ Equillium | Maintains: Buy | $12 → $7 | $0.68 | +929.41% | 1 | Mar 24, 2023 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $23 → $25 | $42.34 | -40.95% | 1 | Jun 17, 2022 | |
| FOLD Amicus Therapeutics | Upgrades: Buy | n/a | $9.85 | - | 3 | Nov 15, 2021 | |
| NTLA Intellia Therapeutics | Initiates: Buy | n/a | $22.15 | - | 1 | Sep 24, 2021 | |
| SRZN Surrozen | Initiates: Buy | $285 | $10.22 | +2,688.65% | 1 | Sep 7, 2021 | |
| PRQR ProQR Therapeutics | Initiates: Buy | n/a | $1.65 | - | 1 | May 3, 2021 | |
| CRBP Corbus Pharmaceuticals Holdings | Downgrades: Neutral | n/a | $48.01 | - | 2 | Sep 8, 2020 | |
| APLS Apellis Pharmaceuticals | Initiates: Neutral | n/a | $34.98 | - | 1 | Jun 17, 2020 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Neutral | n/a | $6.55 | - | 1 | Jun 17, 2020 | |
| IFRX InflaRx | Initiates: Buy | n/a | $1.73 | - | 1 | Jun 17, 2020 | |
| DBVT DBV Technologies | Maintains: Outperform | $120 → $98 | $0.77 | +12,595.95% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $33.68
Upside: +95.96%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $40.96
Upside: +210.06%
Abeona Therapeutics
May 30, 2024
Initiates: Buy
Price Target: $21
Current: $4.12
Upside: +409.71%
Krystal Biotech
Apr 16, 2024
Reiterates: Buy
Price Target: $178 → $204
Current: $177.61
Upside: +14.86%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $5.00
Upside: +700.00%
Soleno Therapeutics
Jan 23, 2024
Initiates: Buy
Price Target: $63
Current: $39.73
Upside: +58.57%
Editas Medicine
Sep 29, 2023
Upgrades: Buy
Price Target: $9 → $17
Current: $4.54
Upside: +274.45%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $19.78
Upside: +142.67%
Fulcrum Therapeutics
Aug 22, 2023
Upgrades: Buy
Price Target: $11
Current: $6.10
Upside: +80.33%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $5.28
Upside: +240.91%
Equillium
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.68
Upside: +929.41%
Rhythm Pharmaceuticals
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $42.34
Upside: -40.95%
Amicus Therapeutics
Nov 15, 2021
Upgrades: Buy
Price Target: n/a
Current: $9.85
Upside: -
Intellia Therapeutics
Sep 24, 2021
Initiates: Buy
Price Target: n/a
Current: $22.15
Upside: -
Surrozen
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $10.22
Upside: +2,688.65%
ProQR Therapeutics
May 3, 2021
Initiates: Buy
Price Target: n/a
Current: $1.65
Upside: -
Corbus Pharmaceuticals Holdings
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $48.01
Upside: -
Apellis Pharmaceuticals
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $34.98
Upside: -
BioCryst Pharmaceuticals
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $6.55
Upside: -
InflaRx
Jun 17, 2020
Initiates: Buy
Price Target: n/a
Current: $1.73
Upside: -
DBV Technologies
Oct 23, 2017
Maintains: Outperform
Price Target: $120 → $98
Current: $0.77
Upside: +12,595.95%